Show simple item record

Carfilzomib en el tratamiento de mieloma múltiple: revisión sistemática de la literatura y experiencia colombiana basada en RIPS

dc.contributor.authorCastaneda, Camilospa
dc.contributor.authorPantoja, María Camilaspa
dc.contributor.authorMontaño, Luzmilaspa
dc.contributor.authorRosselli, Diegospa
dc.date.accessioned2020-10-27T14:20:08Z
dc.date.available2020-10-27T14:20:08Z
dc.date.issued2014-11-04
dc.identifier.issn2382-4603
dc.identifier.issn0123-7047
dc.identifier.urihttp://hdl.handle.net/20.500.12749/10136
dc.description.abstractEl mieloma múltiple es un tumor maligno y progresivo de las células B asociado a lesiones osteolíticas, inmunodeficiencia y disfunción renal que ha sido tratado desde 2008 con bortezomib con el cual se logró un aumento del tiempo de sobrevida de los pacientes, sin embargo su uso se vio limitado por efectos adversos dependientes de la dosis, en especial la neuropatía periférica dolorosa. Recientemente ha entrado en uso carfilzomib (agente inhibidor de proteosoma de segunda generación) aprobado por la FDAen 2012 como agente único para tratamiento de enfermedad refractaria y recaídas de mieloma múltiple.spa
dc.format.mimetypeapplication/pdfspa
dc.language.isospaspa
dc.publisherUniversidad Autónoma de Bucaramanga UNAB
dc.relationhttps://revistas.unab.edu.co/index.php/medunab/article/view/2306/1991
dc.relation.urihttps://revistas.unab.edu.co/index.php/medunab/article/view/2306
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/2.5/co/
dc.sourceMedUNAB; Vol. 17 Núm. 2 (2014): Agosto - Noviembre de 2014: Mieloma múltiple, Aloinmunización eritrocitaria, Riesgo cardiovascular; 99-106
dc.titleCarfilzomib en el tratamiento de mieloma múltiple: revisión sistemática de la literatura y experiencia colombiana basada en RIPS
dc.title.translatedCarfilzomib for the treatment of multiple myeloma: systematic review of the literature and colombian experience based on RIPSeng
dc.title.translatedCarfilzomib no tratamento do mieloma múltiplo: revisão da literatura e da experiência colombiana baseada em RIPS
dc.publisher.facultyFacultad Ciencias de la Salud
dc.publisher.programPregrado Medicina
dc.type.driverinfo:eu-repo/semantics/article
dc.type.localArtículospa
dc.type.coarhttp://purl.org/coar/resource_type/c_6501
dc.subject.keywordsMultiple myelomaeng
dc.subject.keywordsPolyneuropathieseng
dc.subject.keywordsProteosome inhibitorseng
dc.subject.keywordsMieloma múltiploeng
dc.subject.keywordsPolineuropatiaeng
dc.subject.keywordsInibidores de proteassomaeng
dc.identifier.instnameinstname:Universidad Autónoma de Bucaramanga UNABspa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersion
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.relation.referencesSiegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S, et al. Aphase 2 study of single-agent carfilzomib ( PX-171-003-A1 ) in patients with relapsed and refractory multiple myeloma. Blood. 2014 Oct 4;120(14):2817-25
dc.relation.referencesRedic K. Carfilzomib: a novel agent for multiple myeloma. J Pharm Pharmacol. 2013 Aug;65(8):1095-106
dc.relation.referencesRaabMS,PodarK,BreitkreutzI,RichardsonPG, AndersonKC.Multiplemyeloma.Lancet.2009Jul 25;374(9686):324-39
dc.relation.referencesKyle R, Gertz M, Witzig TE, Lust J, Lacy MQ, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003 Jan;78(1):21-33
dc.relation.referencesRichardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. Aphase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003 June 26;348:2609-17
dc.relation.referencesKumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia. 2012 Jan;26(1):149-57
dc.relation.referencesAnderson KC, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Cohen AD, et al. NCCNclinical practice guidelines in oncology: multiple myeloma. J Natl Compr Canc Netw. 2009 Oct 7;7(9):908-42
dc.relation.referencesDemo SD, Kirk CJ, Aujay M, Buchholz TJ, Dajee M, Ho MN,etal.AntitumoractivityofPR-171,anovel irreversible inhibitor of the proteasome. Cancer Res. 2007 Jul 1;67(13):6383-91
dc.relation.referencesDemo SD, Kirk CJ, Aujay M, Buchholz TJ, Dajee M, Ho MN,etal.AntitumoractivityofPR-171,anovel irreversible inhibitor of the proteasome. Cancer Res. 2007 Jul 1;67(13):6383-91
dc.relation.referencesRajkumar SV, Richardson PG, Hideshima T, Anderson KC. Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol. 2005 Jan 20;23(3):630-9
dc.relation.referencesKim HB, Myung J, Sin N, Crews CM. Proteasome inhibitionbythenaturalproductsepoxomicinand dihydroeponemycin: insights into specificity and potency. Bioorg Med Chem Lett. 1999 Dec 6;9(23):3335-40
dc.relation.referencesMeng L, Kwok BH, Sin N, Crews CM. Eponemycin exerts its antitumor effect through the inhibition of proteasome function. Cancer Res. 1999 Jun 15;59(12):2798-801
dc.relation.referencesArastu-Kapur S, Anderl JL, Kraus M, Parlati F, Shenk KD, Lee SJ, et al. Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverseevents.ClinCancerRes.2011May 1;17(9):2734-43
dc.relation.referencesSinghalS,SiegelDS,MartinT,VijR,WangL, Jakubowiak AJ, et al. Integrated safety from phase 2 studiesofmonotherapycarfilzomibinpatientswith relapsed and refractory multiple myeloma (MM): an updated analysis. Poster session presented at: Myeloma - Therapy, excluding Transplantation. Proceedings of the 53rd ASHAnnual Meeting & Exposition; 2011 Dec 10; San Diego, CA
dc.relation.referencesSiegel D, Martin T, Nooka A, Harvey RD, Vij R, Niesvizky R,etal.Integratedsafetyprofileofsingle-agent carfilzomib: experience from 526 patients enrolled in 4 phaseIIclinicalstudies.Haematologica.2013 Nov;98(11):1753-61
dc.relation.referencesNooka AK, Badros AZ, Patel P, McCulloch L, Lonial S, Kaufman JL.. Hematologic safety data from four phase IIstudies of single-agent carfilzomib in relapsed and/or refractory multiple myeloma. Poster session presented at: General Poster Session, Lymphoma and Plasma Cell Disorders.Proceedingsofthe2012ASCOAnnual Meeting. J Clin Oncol. 2012;30 Suppl; abstr 8086
dc.relation.referencesJagannath S, Vij R, Stewart AK, Trudel S, Jakubowiak AJ, Reiman T, et al. An open-label single-arm pilot phase IIstudy (PX- 171-003-A0) of low-dose, single-agent carfilzomibinpatientswithrelapsedandrefractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2012 Oct;12(5):310-8
dc.relation.referencesRosselli D, Rueda JD. Burden of pneumococcal infection in adults in Colombia. J Infect Public Health. 2012 Oct;5(5):354-9
dc.relation.referencesBernal O, Forero JC, Villamil P, Pino R. Disponibilidad de datos y perfil de morbilidad en Colombia. Rev Panam Salud Pública. 2012;31(3):181-7. Españo
dc.relation.referencesJakubowiak a J, Siegel DS, Martin T, Wang M, Vij R, Lonial S, et al. Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study. Leukemia. 2013 Dec;27(12):2351-6
dc.relation.referencesNiesvizky R, Martin TG, Bensinger WI, Alsina M, Siegel DS, Kunkel L, et al. Phase Ib dose-escalation study (PX-171-006)ofcarfilzomib,lenalidomide,andlow-dose dexamethasoneinrelapsedorprogressivemultiple myeloma. Clin Cancer Res. 2013 Apr 15;19(8):2248-56
dc.relation.referencesO'Connor OA, Stewart AK, Vallone M, Molineaux CJ, KunkelLA,GerecitanoJF,etal.Aphase1dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clin Cancer Res. 2009 Nov 15;15(22):7085-91
dc.relation.referencesAlsina M, Trudel S, Furman RR, Rosen PJ, O'Connor O a, Comenzo RL, et al. Aphase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma. Clin Cancer Res. 2012 Sep 1;18(17):4830-40
dc.relation.referencesBerenson JR, Hilger JD, Yellin O, Dichmann R, Patel-Donnelly D, Boccia RV, et al. Replacement of bortezomib withcarfilzomibformultiplemyelomapatients progressingfrombortezomibcombinationtherapy. Leukemia. 2014 Jul;28(7):1529-36
dc.relation.referencesVij R, Siegel DS, Jagannath S, Jakubowiak AJ, Stewart AK, McDonagh K, et al. An open-label, single-arm, phase 2studyofsingle-agentcarfilzomibinpatientswith relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. Br J Haematol. 2012 Sep 1;158(6):739-48
dc.relation.referencesBecker N. Epidemiology of multiple myeloma. Recent Results Cancer Res. 2011;183:25-35
dc.relation.referencesSuzukiK.Currenttherapeuticstrategyformultiple myeloma. Jpn J Clin Oncol. 2013;43(2):116-24
dc.subject.lembCiencias de la salud
dc.subject.lembMedicina
dc.subject.lembCiencias de la vida
dc.identifier.repourlrepourl:https://repository.unab.edu.co
dc.description.abstractenglishMultiple myeloma is a malignant and progressive B-cell tumor associated with osteolytic lesions, immunodeficiency and renal dysfunction that has been treated with bortezomib since 2008, with which an increase in the survival time of patients was achieved, however its use is was limited by dose-dependent adverse effects, especially painful peripheral neuropathy. Recently, carfilzomib (a second-generation proteasome inhibitor agent) approved by the FDA in 2012 as a single agent for the treatment of refractory disease and relapses of multiple myeloma has come into use.eng
dc.subject.proposalMielomamúltiplo
dc.subject.proposalPolineuropatia
dc.subject.proposalCarfilzomib
dc.subject.proposalInibidores de proteassoma
dc.subject.proposalBortezomib
dc.identifier.doi10.29375/01237047.2306
dc.type.redcolhttp://purl.org/redcol/resource_type/ART


Files in this item

Thumbnail
Name:
2014_Carfilzomib_en_el_tratami ...
Size:
666.5Kb
Format:
PDF
Description:
Articulo
View/Open

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by-nc-nd/2.5/co/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by-nc-nd/2.5/co/